Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF91UW
|
|||
| Drug Name |
Tildacerfont
|
|||
| Synonyms |
Tildacerfont; 1014983-00-6; 4-(4-chloro-5-(2,5-dimethyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)thiazol-2-yl)morpholine; SCHEMBL2182127; XVAWSBAQNIXMIO-UHFFFAOYSA-N; AKOS040747540; MS-27364; HY-113603; 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-7-(1-ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine; 4-[4-chloro-5-(2,5-dimethyl-7-pentan-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)-1,3-thiazol-2-yl]morpholine; 7-(1-ethyl-propyl)-3-(4-chloro-2-morpholin-4-yl-thiazol-5-yl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Congenital adrenal hyperplasia [ICD-11: 5A71.01; ICD-10: E25.0] | Phase 2 | [1] | |
| Company |
Spruce Biosciences Dale City, CA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H26ClN5OS
|
|||
| Canonical SMILES |
CCC(CC)C1=CC(=NC2=C(C(=NN12)C)C3=C(N=C(S3)N4CCOCC4)Cl)C
|
|||
| InChI |
InChI=1S/C20H26ClN5OS/c1-5-14(6-2)15-11-12(3)22-19-16(13(4)24-26(15)19)17-18(21)23-20(28-17)25-7-9-27-10-8-25/h11,14H,5-10H2,1-4H3
|
|||
| InChIKey |
XVAWSBAQNIXMIO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Corticotropin-releasing factor receptor 1 (CRHR1) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Long-term depression | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Panther Pathway | Cortocotropin releasing factor receptor signaling pathway | |||
| Reactome | Class B/2 (Secretin family receptors) | |||
| G alpha (s) signalling events | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Myometrial Relaxation and Contraction Pathways | ||||
| Corticotropin-releasing hormone | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05370521) A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens. U.S.National Institutes of Health. | |||
| REF 2 | Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.